Drug newcomers: recently launched products spending to advertise in professional health journals
Among the top 20 drugs advertising in professional health journals from the beginning of 2013 until the end of August, several of those products are newcomers to the list and did not appear at this time in 2012.
First off is Invokana, which launched in April, and currently ranks as second in terms of its spend in professional health journal advertising ($9 MM). Linzess, which currently ranks third on the list with a $6 MM year-to-date investment in professional health journal advertising, launched in December 2012.
Other newer products that rank in the top 20 drugs advertising in professional health journals through August 2013 are:
- Xeljanz - $3 MM
- Namenda XR - $3 MM
- Xtandi Capsules - $2 MM
- Abilify Maintena Injection - $2 MM
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date